PubMed Health⌕ Search

PubMed · 15819943

High-resolution slug testing.

Abstract

The hydraulic conductivity (K) variation has important ramifications for ground water flow and the transport of contaminants in ground water. The delineation of the nature of that variation can be critical to complete characterization of a site and the planning of effective and efficient remedial measures. Site-specific features (such as high-conductivity zones) need to be quantified. Our alluvial field site in the Kansas River valley exhibits spatial variability, very high conductivities, and nonlinear behavior for slug tests in the sand and gravel aquifer. High-resolution, multilevel slug tests have been performed in a number of wells that are fully screened. A general nonlinear model based on the Navier-Stokes equation, nonlinear frictional loss, non-Darcian flow, acceleration effects, radius changes in the wellbore, and a Hvorslev model for the aquifer has been used to analyze the data, employing an automated processing system that runs within the Excel spreadsheet program. It is concluded that slug tests can provide the necessary data to identify the nature of both horizontal and vertical K variation in an aquifer and that improved delineation or higher resolution of K structure is possible with shorter test intervals. The gradation into zones of higher conductivity is sharper than seen previously, and the maximum conductivity observed is greater than previously measured. However, data from this project indicate that well development, the presence of fines, and the antecedent history of the well are important interrelated factors in regard to slug-test response and can prevent obtaining consistent results in some cases.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

G M Zemansky, C D McElwee. High-resolution slug testing.. https://doi.org/10.1111/j.1745-6584.2005.0008.x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Clinical applications of newer radionuclide therapies.

When radio-iodine was first used in the treatment of metastasized thyroid carcinoma in 1943, its success in terms of tumour response, quality of life improvement and survival was considered a 'miracle', as in those days metastatic cancer was generally fatal. Inspired by this, many efforts have been made to apply radioisotope therapy to other tumours. Radionuclide therapy uses radioactive isotopes labelled with specific targeting agents that aim to deliver the irradiation of the isotope to the tumour, while sparing normal tissues. Its unique modality allows to systemically target radiosensitive tumours throughout the body. Another important principle is its so-called 'cross-fire' action, whereby, owing to the larger reach of the radiation in relation to the cell diameter, a tumour cell receives lethal hits also from isotopes in the neighbourhood that are not directly associated with this cell. The treatment is therefore less hampered by inhomogeneous distribution and metabolism than for example chemo- or immunotherapy. The European Association of Nuclear Medicine has issued guidelines on so-called 'established' therapies (www.eanm.org), i.e. hyperthyroidism, thyroid carcinoma, refractory synovitis, bone metastases, mIBG therapy, 32P therapy and Lipiodol therapy. Newer therapies include radio-peptide therapy, radio-immunotherapy of lymphoma and microsphere therapy for liver cancer. The aim of a recently held workshop at the ECCO13 conference 2005 and this review is to inform the oncology community about these new developing therapies.

Forecasting↗